Bicycle Therapeutics (NASDAQ:BCYC – Get Free Report) and CAMP4 Therapeutics (NASDAQ:CAMP – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, dividends and earnings.
Institutional & Insider Ownership
86.2% of Bicycle Therapeutics shares are owned by institutional investors. 22.0% of Bicycle Therapeutics shares are owned by insiders. Comparatively, 21.7% of CAMP4 Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares Bicycle Therapeutics and CAMP4 Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Bicycle Therapeutics | $72.86 million | 2.78 | -$218.96 million | ($2.03) | -1.43 |
| CAMP4 Therapeutics | $5.32 million | 44.71 | -$80.40 million | ($2.14) | -1.77 |
CAMP4 Therapeutics has lower revenue, but higher earnings than Bicycle Therapeutics. CAMP4 Therapeutics is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Bicycle Therapeutics has a beta of 1.59, indicating that its share price is 59% more volatile than the S&P 500. Comparatively, CAMP4 Therapeutics has a beta of 0.28, indicating that its share price is 72% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent recommendations for Bicycle Therapeutics and CAMP4 Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bicycle Therapeutics | 1 | 4 | 5 | 0 | 2.40 |
| CAMP4 Therapeutics | 1 | 1 | 8 | 1 | 2.82 |
Bicycle Therapeutics currently has a consensus price target of $13.57, suggesting a potential upside of 368.79%. CAMP4 Therapeutics has a consensus price target of $10.44, suggesting a potential upside of 175.58%. Given Bicycle Therapeutics’ higher possible upside, equities research analysts clearly believe Bicycle Therapeutics is more favorable than CAMP4 Therapeutics.
Profitability
This table compares Bicycle Therapeutics and CAMP4 Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Bicycle Therapeutics | -169.75% | -26.02% | -22.30% |
| CAMP4 Therapeutics | -2,276.33% | -182.39% | -74.87% |
Summary
Bicycle Therapeutics beats CAMP4 Therapeutics on 10 of the 15 factors compared between the two stocks.
About Bicycle Therapeutics
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing medicines for serious diseases, with a focus on cancer. Founded in 2009, the company grew out of research at the University of Cambridge in the United Kingdom and has operations in Cambridge, UK, and Cambridge, Massachusetts. The company’s proprietary Bicycle platform creates small, constrained peptides that can bind to specific biological targets. Bicycle Therapeutics is using this technology to develop treatments that may be designed to reach targets that are difficult for conventional drugs to access.
About CAMP4 Therapeutics
CAMP4 Therapeutics is a clinical-stage biotechnology company developing RNA-based medicines for genetic diseases in which the body produces too little of an essential protein. The company’s research focuses on increasing the expression of selected genes to address these protein deficiencies. Its Regulatory Action on RNA (RAP) platform is designed to identify regulatory RNAs that influence gene expression. CAMP4 uses antisense oligonucleotides to target these RNAs, with the goal of adjusting the activity of disease-related genes.
Receive News & Ratings for Bicycle Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicycle Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
